J.P. Morgan analysts said the CMS’ review “validates the technology and could potentially move the needle on growth for Medtronic.”

medtechdive.com

CMS starts Medicare coverage analysis for Medtronic, Recor renal denervation devices

More than a decade ago, Medtronic announced that a pivotal trial testing its renal denervation system had failed. Though it got approved later, reimbursement has been elusive. All that might change this year. The post Is Medtronic On the Cusp of Rewriting the Story of Renal Denervation? appeared first on MedCity News.

MedCity News

Is Medtronic On the Cusp of Rewriting the Story of Renal Denervation?

January 13, 2025—Medtronic and Recor Medical, Inc. separately announced that the Centers for Medicare & Medicaid Services (CMS) is opening a national coverage analysis (NCA; CAG-00470N) on renal denervation (RDN) for uncontrolled hypertension. CMS’s expected completion date for the NCA is October 11, 2025. Both companies noted that the NCA process will allow the agency to review and develop a national Medicare coverage policy in a National Cover…

Endovascular Today

CMS Initiates NCA on Renal Denervation for Uncontrolled Hypertension - Endovascular Today

More than a decade ago, Medtronic announced that a pivotal trial testing its renal denervation system had failed. Though the system was later approved by the FDA, reimbursement has been elusive. All that might change this year.At the 43rd annual J.P. Morgan Healthcare Conference on Monday, Medtronic CEO Geoff Martha mixed in some breaking news [...]

ramaonhealthcare.com

Is Medtronic On the Cusp of Rewriting Its Own Story in Renal Denervation? – RamaOnHealthcare

Media Bias/Fact Check

Cleveland Clinic The Centers for Medicare & Medicaid Services (CMS) is opening a national coverage analysis (NCA) on renal denervation, with a view to reviewing and developing a national Medicare coverage policy for the therapy for patients with hypertension. The expected completion date for the national coverage analysis is 11 October 2025. Until a national coverage determination is put into effect, renal denervation procedures will continue to…

Cardiovascular News

CMS launches review of coverage for renal denervation

CMS is accepting public comments on the topic for a period of 30 days. Recor Medical and Medtronic have both shared statements in support of the potential policy shift.

cardiovascularbusiness.com

Momentum continues for renal denervation as CMS considers national Medicare coverage

Interventional News

CMS launches review of coverage for renal denervation - Interventional News

National coverage analysis is the first-of-its kind for a minimally invasive, interventional treatment for high blood pressure.

CMS starts Medicare coverage analysis for Medtronic, Recor renal denervation devices

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics